<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0011512"><a href="http://purl.obolibrary.org/obo/MONDO_0011512">MONDO:0011512</a></h3>
<p><strong>Label:</strong> Brooke-Spiegler syndrome</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0011114">MONDO:0011114</a> (familial multiple trichoepithelioma),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_79493">Orphanet:79493</a>, <a href="http://www.orpha.net/ORDO/Orphanet_867">Orphanet:867</a>, <a href="http://purl.obolibrary.org/obo/OMIM_612099">OMIM:612099</a>, <a href="http://purl.obolibrary.org/obo/OMIM_601606">OMIM:601606</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0200034">HP:0200034</a> (Papule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100585">HP:0100585</a> (Telangiectasia of the skin) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0003581">HP:0003581</a> (Adult onset) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000006">HP:0000006</a> (Autosomal dominant inheritance) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0200034">HP:0200034</a> (Papule) and <a href="http://purl.obolibrary.org/obo/HP_0200036">HP:0200036</a> (Skin nodule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100585">HP:0100585</a> (Telangiectasia of the skin) and <a href="http://purl.obolibrary.org/obo/HP_0200036">HP:0200036</a> (Skin nodule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0011354">HP:0011354</a> (Generalized abnormality of skin) and <a href="http://purl.obolibrary.org/obo/HP_0200036">HP:0200036</a> (Skin nodule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0011276">HP:0011276</a> (Vascular skin abnormality) and <a href="http://purl.obolibrary.org/obo/HP_0200036">HP:0200036</a> (Skin nodule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002597">HP:0002597</a> (Abnormality of the vasculature) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0200036">HP:0200036</a> (Skin nodule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001626">HP:0001626</a> (Abnormality of the cardiovascular system) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0200036">HP:0200036</a> (Skin nodule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001482">HP:0001482</a> (Subcutaneous nodule) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0200034">HP:0200034</a> (Papule) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001482">HP:0001482</a> (Subcutaneous nodule) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0100585">HP:0100585</a> (Telangiectasia of the skin) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001482">HP:0001482</a> (Subcutaneous nodule) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0011354">HP:0011354</a> (Generalized abnormality of skin) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001482">HP:0001482</a> (Subcutaneous nodule) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) and <a href="http://purl.obolibrary.org/obo/HP_0011276">HP:0011276</a> (Vascular skin abnormality) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001482">HP:0001482</a> (Subcutaneous nodule) and <a href="http://purl.obolibrary.org/obo/HP_0002597">HP:0002597</a> (Abnormality of the vasculature) and <a href="http://purl.obolibrary.org/obo/HP_0002671">HP:0002671</a> (Basal cell carcinoma) 62.50%</li>
</ul>
</body>
</html>
